Personalis Has Struggled Since Its IPO - Here's How I'd Play It

The company has a collaboration with Merck, and there are far worse partners you could have when working in the cancer segment of biotech.

GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead

Let's see what we might expect.

Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later

The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.

Emergent BioSolutions Appears on a Healthy Trajectory

Investors may consider dosing up on the long side of this vaccine provider.

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

Lock in Profits on InMode Before They Slip Away

Let's check out two charts.

Johnson & Johnson Finally Shakes Off Its Bad News 'Overhang'

It looks like JNJ has its swagger back.

Let's See How These Three Dividend Aristocrats Stack Up

Two food-related names and one in health care look like promising investments right now.

Cooper Cos. Can Rally Further After Some Sideways Consolidation

Time to review the charts and indicators.

This Dividend Stock Is Tipping the Scales for Investors

As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.